Literature DB >> 23872992

Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment.

K N Wu1, Y J Wang1, Y He1, Y X Hu1, H R Fu1, L X Sheng1, B S Wang1, S Fu1, H Huang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23872992     DOI： 10.1038/leu.2013.221

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

Authors:  Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

3.  Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis.

Authors:  Cristiana Gioia; Chiara Agrati; Rita Casetti; Cristiana Cairo; Giovanna Borsellino; Luca Battistini; Giorgio Mancino; Delia Goletti; Vittorio Colizzi; Leopoldo P Pucillo; Fabrizio Poccia
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

4.  Decitabine facilitates the generation and immunosuppressive function of regulatory γδT cells derived from human peripheral blood mononuclear cells.

Authors:  Y Hu; Q Cui; Y Gu; L Sheng; K Wu; J Shi; Y Tan; H Fu; L Liu; S Fu; X Yu; H Huang
Journal:  Leukemia       Date:  2012-11-29       Impact factor: 11.528

5.  Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.

Authors:  Julie Gertner-Dardenne; Remy Castellano; Emilie Mamessier; Slaveia Garbit; Eloïse Kochbati; Anne Etienne; Aude Charbonnier; Yves Collette; Norbert Vey; Daniel Olive
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

6.  Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.

Authors:  Haishan Li; C David Pauza
Journal:  Cancer Immunol Immunother       Date:  2010-11-25       Impact factor: 6.968

7.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Authors:  S Mustjoki; M Ekblom; T P Arstila; I Dybedal; P K Epling-Burnette; F Guilhot; H Hjorth-Hansen; M Höglund; P Kovanen; T Laurinolli; J Liesveld; R Paquette; J Pinilla-Ibarz; A Rauhala; N Shah; B Simonsson; M Sinisalo; J L Steegmann; L Stenke; K Porkka
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

Review 8.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Authors:  Ellen Weisberg; Paul W Manley; Sandra W Cowan-Jacob; Andreas Hochhaus; James D Griffin
Journal:  Nat Rev Cancer       Date:  2007-05       Impact factor: 60.716

9.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Authors:  Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Authors:  Julia Salih; Julia Hilpert; Theresa Placke; Frank Grünebach; Alexander Steinle; Helmut Rainer Salih; Matthias Krusch
Journal:  Int J Cancer       Date:  2010-11-01       Impact factor: 7.396
View more
  3 in total

1.  Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro.

Authors:  Xiaohuan Liu; Ting Feng; Tianxiang Gong; Chongyang Shen; Tingting Zhu; Qihong Wu; Qiang Li; Hong Li
Journal:  Biomed Res Int       Date:  2015-04-14       Impact factor: 3.411

2.  Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.

Authors:  Hao Zhang; Yongxian Hu; Mi Shao; Xinyi Teng; Penglei Jiang; Xiujian Wang; Hui Wang; Jiazhen Cui; Jian Yu; Zuyu Liang; Lijuan Ding; Yingli Han; Jieping Wei; Yulin Xu; Xiaoqing Li; Wei Shan; Jimin Shi; Yi Luo; Pengxu Qian; He Huang
Journal:  J Hematol Oncol       Date:  2021-07-21       Impact factor: 17.388

3.  Innate T-αβ lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinib.

Authors:  Jean-Marc Gombert; André Herbelin; Alice Barbarin; Myriam Abdallah; Lucie Lefèvre; Nathalie Piccirilli; Emilie Cayssials; Lydia Roy
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.